• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外周血管腔内支架置入术的炎症标志物与再狭窄:当前概念

Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts.

作者信息

Joviliano Edwaldo Edner, Piccinato Carlos Eli, Dellalibera-Joviliano Renata, Moriya Takachi, Évora Paulo R B

机构信息

Division of Vascular and Endovascular Surgery, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

出版信息

Ann Vasc Surg. 2011 Aug;25(6):846-55. doi: 10.1016/j.avsg.2011.02.026. Epub 2011 May 28.

DOI:10.1016/j.avsg.2011.02.026
PMID:21620656
Abstract

In this article, we review the current status of inflammation linked to percutaneous transluminal angioplasty with stent implantation, especially as it relates to restenosis and its clinical implications. Common to multiple vascular diseases, including atherosclerosis, interventional restenosis is a localized inflammatory reaction. Activated smooth muscle cells respond to local inflammation and migrate from the media into the lumen of the vessel, where they proliferate and synthesize cytokines which they respond to in an autocrine manner, sustaining the progression of the lesion. The deleterious effects of proinflammatory cytokines, particularly immunomodulatory interleukins, on vascular pathophysiology and development of these maladaptive processes have been the subject of intense study. Matrix metalloproteinases and tissue inhibitors of metalloproteinases are important in many physiologic and pathologic processes and their expression is related with the classic cardiovascular risk factors as well as with inflammation. They seem to play a central role in atherosclerosis and restenosis. The primary use of drug-eluting stents has become routine clinical practice for coronary artery disease, but the use in peripheral arteries remains to be further studied, like that demonstrated in sirolimus-coated Cordis trials. New studies to understand this complex process in peripheral arteries are warranted.

摘要

在本文中,我们回顾了与经皮腔内血管成形术及支架植入相关的炎症的现状,尤其是其与再狭窄的关系及其临床意义。包括动脉粥样硬化在内的多种血管疾病共有的特点是,介入性再狭窄是一种局部炎症反应。活化的平滑肌细胞对局部炎症作出反应,并从血管中层迁移至血管腔内,在那里它们增殖并合成细胞因子,这些细胞因子以自分泌方式对其作出反应,维持病变的进展。促炎细胞因子,特别是免疫调节性白细胞介素,对血管病理生理学和这些适应不良过程发展的有害影响一直是深入研究的课题。基质金属蛋白酶和金属蛋白酶组织抑制剂在许多生理和病理过程中都很重要,它们的表达与经典心血管危险因素以及炎症有关。它们似乎在动脉粥样硬化和再狭窄中起核心作用。药物洗脱支架的主要用途已成为冠状动脉疾病的常规临床实践,但在外周动脉中的应用仍有待进一步研究,如西罗莫司涂层Cordis试验所示。有必要开展新的研究来了解外周动脉中的这一复杂过程。

相似文献

1
Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts.外周血管腔内支架置入术的炎症标志物与再狭窄:当前概念
Ann Vasc Surg. 2011 Aug;25(6):846-55. doi: 10.1016/j.avsg.2011.02.026. Epub 2011 May 28.
2
Drug-eluting stents.药物洗脱支架
Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319.
3
Interleukins and inflammatory markers in in-stent restenosis after femoral percutaneous transluminal angioplasty.股动脉经皮腔内血管成形术后支架内再狭窄中的白细胞介素和炎症标志物
Ann Vasc Surg. 2015;29(4):731-7. doi: 10.1016/j.avsg.2014.12.006. Epub 2015 Feb 25.
4
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.经皮冠状动脉介入治疗的最新进展:药物洗脱支架的演变,聚焦于XIENCE V药物洗脱支架。
Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550.
5
The Role of Interleukins and Inflammatory Markers in the Early Restenosis of Covered Stents in the Femoropopliteal Arterial Segment.白细胞介素和炎症标志物在股腘动脉段覆膜支架早期再狭窄中的作用
Ann Vasc Surg. 2018 Jul;50:88-95. doi: 10.1016/j.avsg.2017.11.064. Epub 2018 Feb 23.
6
Characterization of the kallikrein-kinin system, metalloproteinases, and their tissue inhibitors in the in-stent restenosis after peripheral percutaneous angioplasty.外周经皮血管成形术后支架内再狭窄中激肽释放酶-激肽系统、金属蛋白酶及其组织抑制剂的特征
Ann Vasc Surg. 2014 May;28(4):1005-15. doi: 10.1016/j.avsg.2013.11.014. Epub 2014 Jan 16.
7
Restenosis after stenting of atherosclerotic renal artery stenosis: is there a rationale for the use of drug-eluting stents?动脉粥样硬化性肾动脉狭窄支架置入术后再狭窄:药物洗脱支架的应用是否合理?
Catheter Cardiovasc Interv. 2006 Jul;68(1):125-30. doi: 10.1002/ccd.20773.
8
Drug-eluting stent: the emerging technique for the prevention of restenosis.药物洗脱支架:预防再狭窄的新兴技术。
Minerva Cardioangiol. 2002 Oct;50(5):443-53.
9
Percutaneous revascularization of persistent renal artery in-stent restenosis.经皮血管重建术治疗持续性肾动脉支架内再狭窄
Vasc Med. 2009 Aug;14(3):259-64. doi: 10.1177/1358863X08100386.
10
Role of stents, drug-eluting stents, and stent-grafts in treatment of infrainguinal arterial disease.支架、药物洗脱支架及覆膜支架在下肢动脉疾病治疗中的作用。
Semin Vasc Surg. 2007 Mar;20(1):37-41. doi: 10.1053/j.semvascsurg.2007.02.004.

引用本文的文献

1
SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis.钠-葡萄糖协同转运蛋白2抑制剂可改善冠心病患者的预后并预防支架内再狭窄。
Front Cardiovasc Med. 2024 Jan 11;10:1280547. doi: 10.3389/fcvm.2023.1280547. eCollection 2023.
2
Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta.缬沙坦预防球囊损伤大鼠主动脉中的内膜增生,并抑制 SRSF1 表达和 TLR4-iNOS-ERK-AT1 受体通路。
Physiol Res. 2021 Aug 31;70(4):533-542. doi: 10.33549/physiolres.934579. Epub 2021 Jun 1.
3
A Multilayer Functionalized Drug-Eluting Balloon for Treatment of Coronary Artery Disease.
一种用于治疗冠状动脉疾病的多层功能化药物洗脱球囊。
Pharmaceutics. 2021 Apr 23;13(5):614. doi: 10.3390/pharmaceutics13050614.
4
The relationship between neutrophil-lymphocyte ratio and in-stent restenosis in superficial femoral artery.中性粒细胞-淋巴细胞比值与股浅动脉支架内再狭窄的关系。
Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20193448.
5
Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease.血小板与淋巴细胞比值预测股腘动脉疾病药物涂层球囊 6 个月通畅率。
BMC Cardiovasc Disord. 2020 Jan 9;20(1):9. doi: 10.1186/s12872-019-01314-1.
6
Primary stenting for femoropopliteal peripheral arterial disease: analysis up to 24 months.股腘动脉周围动脉疾病的初次支架置入术:长达24个月的分析
J Vasc Bras. 2019 Jan 30;18:e20160104. doi: 10.1590/1677-5449.010416. eCollection 2019.
7
Pro-resolving lipid mediators in vascular disease.血管疾病中的促解决脂质介质。
J Clin Invest. 2018 Aug 31;128(9):3727-3735. doi: 10.1172/JCI97947.
8
Delivery of viral vectors for gene therapy in intimal hyperplasia and restenosis in atherosclerotic swine.载病毒载体基因治疗内膜增生和动脉粥样硬化猪再狭窄。
Drug Deliv Transl Res. 2018 Aug;8(4):918-927. doi: 10.1007/s13346-017-0409-0.
9
Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis.全身性3型五聚体蛋白水平反映了大动脉炎中的血管强化及病情进展。
Arthritis Res Ther. 2014 Nov 14;16(6):479. doi: 10.1186/s13075-014-0479-z.
10
The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?心血管医学中的下降效应:心血管药物和支架对心血管事件的影响是否随着时间的推移而下降?
Korean Circ J. 2013 Jul;43(7):443-52. doi: 10.4070/kcj.2013.43.7.443.